人二倍体细胞2BS株和KMB17株在疫苗研发中的应用  

Application of human diploid cell strains 2BS and KMB17 in vaccine research

作　　者：叶华跃 杨二霞(综述) 姜莉(审校) Ye Huayue;Yang Erxia;Jiang Li(Taizhou Medical Hi-tech Zone Vaccine Engineering Center,Taizhou 225300,China;Research and Development Department,Jiangsu ConVac Bioscience and Technology Co.,Ltd.,Taizhou 225300,China)

机构地区：[1]泰州医药高新技术产业园区疫苗工程中心,225300 [2]艾美康淮生物制药(江苏)有限公司研发部,泰州225300

出　　处：《国际生物制品学杂志》2019年第1期29-33,共5页International Journal of Biologicals

摘　　要：人二倍体细胞是WHO认可的更安全的疫苗生产用细胞基质,已成为全世界疫苗生产首选的细胞基质.我国自主研制的二倍体细胞2BS株和KMB17株来源于人胚肺细胞,因其无致癌性、无外源因子污染,且细胞性状比较稳定,越来越多地在人用疫苗研发与生产中使用.由于2BS和KMB17细胞对多种病毒具有敏感性,因此也作为细胞基质被应用于许多病毒性疫苗的研究开发.目前,用这两种人二倍体细胞生产的疫苗,包括甲型肝炎疫苗、脊髓灰质炎疫苗和肠道病毒71型灭活疫苗等,已在我国广泛上市.Human diploid cells are the cell matrix for safer vaccine production approved by WHO,and have become the first choice for vaccine production in the world.The diploid 2BS and KMB17 strains independently developed in China are derived from human embryonic lung cells.Because they have no carcinogenicity,no xenobiotic pollutants and relatively stable cell characteristics,they are used more and more often in human vaccine development and production.Since 2BS and KMB17 cells are sensitive to a variety of viruses,they have also been used as cell substrates in the development of many viral vaccines.The vaccines produced by these two kinds of human diploid cells have been widely marketed in China,including hepatitis A vaccine,poliovirus vaccine,and inactivated enterovirus 71 vaccine.

关 键 词：人二倍体细胞 研究 疫苗 病毒 

分 类 号：R392[医药卫生—免疫学]